This book fulfils an urgent need for an updated text on pediatric psychopharmacology, and takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones.

The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g., schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo.

It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.

Publication Year: 2012
Edition: 3rd
Author/Editor: Rosenberg, David; Gershon, Samuel
Publisher: Wiley
Doody’s Star Rating®: ★★★★★ Score: 94
Platform: Ovid
Product Type: Book
Speciality: Psychiatry, Psychopharmacology
Language: English
Pages: 474
Illustrations: 0
Included In: Wiley Doody’s Premier Titles Collection 2014